News -

Bioprocess Materials

JSR Life Sciences is proudly providing materials that contribute to the manufacturing process of biopharmaceuticals using integrated technologies of precision polymer synthesis, surface modification, and genetic engineering.

As a first step, JSR Life Sciences offers protein A affinity media that is an indispensable component in the purification process of mono- and polyclonal antibody drugs.

JSR Protein A Affinity Media - "Amsphere™ Protein A JWT203"

JLS has developed a novel protein A media for downstream processing of bio-molecules through Poronomics™, our proprietary technology for the design of hydrophilic and porous resins with large surface area. Due to its characteristics of high dynamic binding capacity, high alkaline resistance, high flow rate compatibility, and sharp elution profile, easy packing and affordable price, JSR protein A affinity media offers the biopharmaceutical industry great utility from both a technical and business perspective.


Related links

Topics

  • Medical research

Contacts

Geert Lissens

Press contact EU Sales Manager for JSR Life Sciences Sales of JSR Life Science products in Europe 0032497522755

Related media

Bioprocess Materials
  • Bioprocess Materials
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
  • File format: .pdf
Download

Related content

Strategic Investment by JSR in Biopharmaceutical Purification Technologies

Tokyo, Japan, February 14, 2013 - JSR Corporation (President: Mitsunobu Koshiba) has signed a strategic partnership agreement with ChromaCon AG (headquartered in Zurich, Switzerland), a private company providing biopharmaceutical purification process technologies. See http://www.jsrlifesciences.com/jsr_e/news/20130214.shtml

JSR Expands its Biomedical Business by investing in BIA Separations' Unique Purification Technology

Tokyo, Japan, January 18, 2012- JSR Corporation (Head Office: Minato-Ku, Tokyo, President: Mitsunobu Koshiba) and BIA Separations (Head Office: Villach, Managing Director and CEO: Aleš Štrancar) announced that they have entered a strategic partnership which includes a minor equity position by JSR on November 14th 2011.